AmMax Bio is a clinical-stage biotechnology company focused on the
development of innovative therapeutics for cancer patients.
About us
AmMax was founded in 2020 by Larry Hsu, PhD in partnership with Amgen and has built a robust pipeline addressing significant unmet needs for large commercial opportunities based on its CSF1R-targeting platform.
The Company leverages its internal and external expertise in acquiring oncology assets and identifying new mechanisms or applications and developing them into first-in-class and/or best-in-class products.
AmMax's portfolio of drug candidates is led by AMB-066, a potent monoclonal antibody designed to treat patients with colorectal cancer with minimal residual disease (CRC MRD) to avoid or delay recurrence.
Larry Hsu, PhD
Chief Executive Officer
Laura Zhu, PhD, MBA
Chief Business Officer
Dorothy Nguyen, MD
VP, Clinical Development
Kirk Johnson, PhD
Chief Scientific Officer
Laman Alani, PhD
SVP of Product Development
Andrew Sauter
Chief Financial Officer
Larry Hsu, PhD
Chief Executive Officer
John Varian
Independent Board Member
W. Michael Kavanaugh, MD
Independent Board Member
Dave Edwards
Independent Board Member
Jerome Shen, PhD
Board Member
Hong-Jen Chang, MD
Board Member
Jinnyuan Lin
Board Member
Scott Kopetz, MD, PhD, FACP
Van Morris, MD
Alan Venook, MD, FASCO
Scott Paulson, MD
Jeffrey Tyner, PhD
Mark Minden, MD, PhD, FRCPC
Elie Traer, MD, PhD
